The Synergistic Action of a VEGF-Receptor Tyrosine-Kinase Inhibitor and a Sensitizing PDGF-Receptor Blocker Depends upon the Stage of Vascular Maturation

REFERENCES

• Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995; 1: 1024–1028
   PubMed Web of Science ®Google Scholar
• Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005; 97: 512–523
   PubMed Web of Science ®Google Scholar
• Baluk P, Hashizume H, McDonald D M. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005; 15: 102–111
   PubMed Web of Science ®Google Scholar
• Baluk P, Tammela T, Ator E, Lyubynska N, Achen M G, Hicklin D J, Jeltsch M, Petrova T V, Pytowski B, Stacker S A, Yla-Herttuala S, Jackson D G, Alitalo K, McDonald D M. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest 2005; 115: 247–257
   PubMed Web of Science ®Google Scholar
• Benjamin L E, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103: 159–165
   PubMed Web of Science ®Google Scholar
• Benjamin L E, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998; 125: 1591–1598
   PubMed Web of Science ®Google Scholar
• Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neurooncol 2005; 7: 452–464
   Google Scholar
• Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 1287–1295
   PubMed Web of Science ®Google Scholar
• Betsholtz C, Lindblom P, Gerhardt H. Role of pericytes in vascular morphogenesis. EXS 2005; 115–125
   PubMedGoogle Scholar
• Bold G, Altmann K H, Frei J, Lang M, Manley P W, Traxler P, Wietfeld B, Bruggen J, Buchdunger E, Cozens R, Ferrari S, Furet P, Hofmann F, Martiny-Baron G, Mestan J, Rosel J, Sills M, Stover D, Acemoglu F, Boss E, Emmenegger R, Lasser L, Masso E, Roth R, Schlachter C, Vetterli W. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J Med Chem 2000; 43: 2310–2323
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Regenass U, Lydon N B. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci U S A 1995; 92: 2558–2562
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932–936
   PubMed Web of Science ®Google Scholar
• Djonov V, Baum O, Burri P H. Vascular remodeling by intussusceptive angiogenesis. Cell Tissue Res 2003; 314: 107–117
   PubMed Web of Science ®Google Scholar
• Djonov V, Schmid M, Tschanz S A, Burri P H. Intussusceptive angiogenesis: its role in embryonic vascular network formation. Circ Res 2000; 86: 286–292
   PubMed Web of Science ®Google Scholar
• Djonov V G, Galli A B, Burri P H. Intussusceptive arborization contributes to vascular tree formation in the chick chorio-allantoic membrane. Anat Embryol (Berl) 2000; 202: 347–357
   Google Scholar
• Djonov V G, Kurz H, Burri P H. Optimality in the developing vascular system: branching remodeling by means of intussusception as an efficient adaptation mechanism. Dev Dyn 2002; 224: 391–402
   PubMedGoogle Scholar
• Dor Y, Djonov V, Abramovitch R, Itin A, Fishman G I, Carmeliet P, Goelman G, Keshet E. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J 2002; 21: 1939–1947
   PubMed Web of Science ®Google Scholar
• Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Muller M, Wood J, Martiny-Baron G, Unger C, Marme D. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 2000; 60: 4819–4824
   PubMed Web of Science ®Google Scholar
• Erber R, Thurnher A, Katsen A D, Groth G, Kerger H, Hammes H P, Menger M D, Ullrich A, Vajkoczy P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004; 18: 338–340
   PubMed Web of Science ®Google Scholar
• Ferrara N, Chen H, Davis-Smyth T, Gerber H P, Nguyen T N, Peers D, Chisholm V, Hillan K J, Schwall R H. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998; 4: 336–340
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber H P, Le Couter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669–676
   PubMed Web of Science ®Google Scholar
• Ferrara N, Kerbel R S. Angiogenesis as a therapeutic target. Nature 2005; 438: 967–974
   PubMed Web of Science ®Google Scholar
• Gerber H P, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998; 273: 13313–13316
   PubMed Web of Science ®Google Scholar
• Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003; 314: 15–23
   PubMed Web of Science ®Google Scholar
• Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003; 161: 1163–1177
   PubMed Web of Science ®Google Scholar
• Hellstrom M, Gerhardt H, Kalen M, Li X, Eriksson U, Wolburg H, Betsholtz C. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 2001; 153: 543–553
   PubMed Web of Science ®Google Scholar
• Hess C, Vuong V, Hegyi I, Riesterer O, Wood J, Fabbro D, Glanzmann C, Bodis S, Pruschy M. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 2001; 85: 2010–2016
   PubMed Web of Science ®Google Scholar
• Hirschi K K, D'Amore P A. Pericytes in the microvasculature. Cardiovasc Res 1996; 32: 687–698
   PubMed Web of Science ®Google Scholar
• Hull M L, Charnock-Jones D S, Chan C L, Bruner-Tran K L, Osteen K G, Tom B D, Fan T P, Smith S K. Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab 2003; 88: 2889–2899
   PubMed Web of Science ®Google Scholar
• Jain R K. Molecular regulation of vessel maturation. Nat Med 2003; 9: 685–693
   PubMed Web of Science ®Google Scholar
• Jain R K, Booth M F. What brings pericytes to tumor vessels?. J Clin Invest 2003; 112: 1134–1136
   PubMed Web of Science ®Google Scholar
• Jain R K, Duda D G, Clark J W, Loeffler J S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3: 24–40
   PubMedGoogle Scholar
• Jain R K, Munn L L, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2002; 2: 266–276
   PubMed Web of Science ®Google Scholar
• Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, Robinson G S, Adamis A P, Shima D T. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006; 168: 2036–2053
   PubMed Web of Science ®Google Scholar
• Konno S, Iizuka M, Yukawa M, Sasaki K, Sato A, Horie Y, Nanjo H, Fukushima T, Watanabe S. Altered expression of angiogenic factors in the VEGF-Ets-1 cascades in inflammatory bowel disease. J Gastroenterol 2004; 39: 931–939
   Google Scholar
• Lambrechts D, Carmeliet P. Medicine: genetic spotlight on a blood defect. Nature 2004; 427: 592–594
   Google Scholar
• Leong T T, Fearon U, Veale D J. Angiogenesis in psoriasis and psoriatic arthritis: clues to disease pathogenesis. Curr Rheumatol Rep 2005; 7: 325–329
   Google Scholar
• Matschke K, Silva-Azevedo L, Hlushchuk R, Djonov V, Baum O. Annexins as cell-type-specific markers in the developing chicken chorionallantoic membrane. Cell Tissue Res 2006; 323: 395–404
   Google Scholar
• Myllarniemi M, Calderon L, Lemstrom K, Buchdunger E, Hayry P. Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation. FASEB J 1997; 11: 1119–1126
   PubMed Web of Science ®Google Scholar
• Rupnick M A, Panigrahy D, Zhang C Y, Dallabrida S M, Lowell B B, Langer R, Folkman M J. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A 2002; 99: 10730–10735
   PubMed Web of Science ®Google Scholar
• St Croix B, Rago C, Velculescu V, Traverso G, Romans K E, Montgomery E, Lal A, Riggins G J, Lengauer C, Vogelstein B, Kinzler K W. Genes expressed in human tumor endothelium. Science 2000; 289: 1197–1202
   PubMed Web of Science ®Google Scholar
• Stalmans I, Lambrechts D, De Smet F, Jansen S, Wang J, Maity S, Kneer P, von der O M, Swillen A, Maes C, Gewillig M, Molin D G, Hellings P, Boetel T, Haardt M, Compernolle V, Dewerchin M, Plaisance S, Vlietinck R, Emanuel B, Gittenberger-de Groot A C, Scambler P, Morrow B, Driscol D A, Moons L, Esguerra C V, Carmeliet G, Behn-Krappa A, Devriendt K, Collen D, Conway S J, Carmeliet P. VEGF: a modifier of the del22q11 (DiGeorge) syndrome?. Nat Med 2003; 9: 173–182
   PubMed Web of Science ®Google Scholar
• Suthin K, Matsushita K, Machigashira M, Tatsuyama S, Imamura T, Torii M, Izumi Y. Enhanced expression of vascular endothelial growth factor by periodontal pathogens in gingival fibroblasts. J Periodontal Res 2003; 38: 90–96
   PubMed Web of Science ®Google Scholar
• Thomas A L, Morgan B, Drevs J, Unger C, Wiedenmann B, Vanhoefer U, Laurent D, Dugan M, Steward W P. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol 2003; 30: 32–38
   PubMed Web of Science ®Google Scholar
• Tille J C, Pepper M S. Hereditary vascular anomalies: new insights into their pathogenesis. Arterioscler Thromb Vasc Biol 2004; 24: 1578–1590
   Google Scholar
• Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O'Reilly T, Wood J, Zimmermann J. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001; 21: 499–512
   PubMed Web of Science ®Google Scholar
• Wood J M. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy. Medicina (B Aires) 2000; 60: 41–7; 41–47, Suppl 2
   PubMed Web of Science ®Google Scholar
• Wood J M, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch K H, Schneider M R, Drevs J, Martiny-Baron G, Totzke F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178–2189
   PubMed Web of Science ®Google Scholar
• Xia Y P, Li B, Hylton D, Detmar M, Yancopoulos G D, Rudge J S. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003; 102: 161–168
   PubMed Web of Science ®Google Scholar